🔴 Live UK Medicine Shortage Alerts:
Check Now
Check My Medicine Free
Popup - Slide Up Icon

Weight-loss jabs, pregnancy and contraception — the MHRA warning

Source data checked 16 July 2026, 17:17 UTC
Short answer: The MHRA warns that GLP-1 weight-loss and diabetes jabs — including Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide)must not be used during pregnancy, while trying to conceive, or while breastfeeding, because there is not enough safety data to know if they could harm a baby. There is also a specific contraception concern: Mounjaro can make the contraceptive pill less reliable, especially in people who are overweight. If you take the pill, the MHRA advises adding a barrier method (such as condoms) for four weeks after starting Mounjaro and for four weeks after each dose increase, or switching to a non-oral method such as the coil or implant. If you are planning a pregnancy, stop the medicine first — at least two months before for semaglutide and at least one month before for tirzepatide. This page is information, not medical advice, and does not give doses — speak to your prescriber or pharmacist about what is right for you.
Key points

What the MHRA has warned

In June 2025 the MHRA issued advice reminding women and people who can become pregnant to use effective contraception while taking GLP-1 medicines for weight loss or type 2 diabetes, and it updated its patient guidance again in February 2026. The named medicines include semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Mounjaro) and liraglutide (Saxenda, Victoza). The advice has two parts: these medicines must not be used around pregnancy at all, and — for Mounjaro specifically — the contraceptive pill may not work as reliably as usual.

The concern is that too many pregnancies were happening in people taking these medicines without knowing the risks. GLP-1 jabs have not been tested for safety in pregnancy, so the safest approach is to avoid them entirely if there is any chance of becoming pregnant. If you are taking one of these medicines and think you might be pregnant, do not stop suddenly without advice — contact your prescriber or pharmacist promptly and they will guide you.

Why the pill can be less reliable on Mounjaro

The MHRA highlights that Mounjaro (tirzepatide) may reduce the effectiveness of oral contraceptives in people who are overweight. Because of this, if you take the pill and are prescribed Mounjaro, the guidance is to not rely on the pill alone. The MHRA advises you either:

This specific pill-effectiveness warning applies to Mounjaro (tirzepatide). The wider "don't use around pregnancy" advice applies to all GLP-1 medicines. Your pharmacist or a sexual-health clinic can help you choose the method that suits you best — this is free on the NHS.

Planning a pregnancy: how long to stop before trying

Because these medicines stay in the body for a while, the MHRA advises stopping before you start trying to conceive, not at the moment you decide to. The recommended gap differs by medicine:

MedicineBrandsStop before trying to conceive
SemaglutideWegovy, Ozempic, RybelsusAt least 2 months before
TirzepatideMounjaroAt least 1 month before
LiraglutideSaxenda, VictozaStop before trying (no set washout period stated)

These are the MHRA's minimum gaps. Your GP or specialist may advise a different plan depending on your situation, so always agree a timeline with them before stopping a diabetes or weight-management medicine — particularly if you have type 2 diabetes, where your blood sugar will still need managing.

Breastfeeding

The MHRA advises that GLP-1 medicines should not be taken while breastfeeding, because it is not known whether the medicine passes into breast milk or how it might affect a baby. If you are breastfeeding and considering weight-loss or diabetes treatment, discuss the options with your GP or pharmacist first.

What to do if you become pregnant while taking a jab

How to report a side effect (Yellow Card)

If you think you have had a side effect from a GLP-1 medicine — including a suspected contraception failure or a problem in pregnancy — you can report it to the MHRA through the Yellow Card scheme. Reporting is open to patients and carers as well as health professionals, and you do not need to be certain the medicine caused the problem — a suspicion is enough. These reports help the MHRA spot new safety signals. Reporting does not replace getting medical help: if you are unwell, still speak to your pharmacist, GP or NHS 111, and call 999 in an emergency.

Where to get help

Related reading

Track weight-loss jab supply and safety updates

MediWatch checks official DHSC and NHS data daily and alerts you if your medication is affected.

Search shortages free →
Reviewed for source alignment and patient-safety framing: 17 July 2026 · Clinical reviewer: Benjamin Alexander, pharmacist (GPhC-registered) · Report an accuracy issue
Official sources: MHRA: GLP-1 medicines for weight loss and diabetes — what you need to know (updated 5 February 2026) · MHRA news: women on weight-loss jabs must use effective contraception (5 June 2025) · NHS: tirzepatide (contraception, pregnancy, breastfeeding) · MHRA Yellow Card scheme
MediWatch is not medical advice. Always follow your prescription label and ask a pharmacist, GP, specialist, NHS 111, or emergency services if you are unsure or unwell. Data checked daily against official sources.

Find your medication

Search for your prescription medications and we'll monitor them for shortages.

e.g. Sertraline, Elvanse, Estradot, Co-codamol, Creon

Personalised alerts from £3.99/mo · No spam · Cancel anytime